m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00331)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
MAP1LC3B
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | LX2 cell line | Homo sapiens |
Treatment: shMETTL3 LX2 cells
Control: shLuc LX2 cells
|
GSE207909 | |
Regulation |
|
logFC: 6.38E-01 p-value: 4.93E-09 |
More Results | Click to View More RNA-seq Results | |
Representative RIP-seq result supporting the interaction between MAP1LC3B and the regulator | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Regulation | logFC: 1.34E+00 | GSE60213 |
In total 4 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | Knocking down METTL3 prevented Enterovirus 71-induced cell death and suppressed Enterovirus 71-induced expression of Bax while rescuing Bcl-2 expression after Enterovirus 71 infection. Knocking down METTL3 inhibited Enterovirus 71-induced expression of Atg5, Atg7 and Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II). Knocking down METTL3 inhibited Enterovirus 71-induced apoptosis and autophagy. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Enterovirus | ICD-11: 1A2Y | ||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Cell proliferation and metastasis | |||
Cell apoptosis | ||||
Cell autophagy | ||||
In-vitro Model | Schwann cells (A type of glial cell that surrounds neurons) | |||
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as ATG5, ATG7, LC3B, and SQSTM1. beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II). beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Responsed Drug | Chloroquine | Approved | ||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Autophagic lysosome acidification | |||
In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as ATG5, ATG7, LC3B, and SQSTM1. beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II). beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Responsed Drug | Gefitinib | Approved | ||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Autophagic lysosome acidification | |||
In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
Experiment 4 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as ATG5, ATG7, LC3B, and SQSTM1. beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II). beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Responsed Drug | Beta-Elemen | Phase 3 | ||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Autophagic lysosome acidification | |||
In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
Enterovirus [ICD-11: 1A2Y]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | Knocking down METTL3 prevented Enterovirus 71-induced cell death and suppressed Enterovirus 71-induced expression of Bax while rescuing Bcl-2 expression after Enterovirus 71 infection. Knocking down METTL3 inhibited Enterovirus 71-induced expression of Atg5, Atg7 and Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II). Knocking down METTL3 inhibited Enterovirus 71-induced apoptosis and autophagy. | |||
Responsed Disease | Enterovirus [ICD-11: 1A2Y] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Cell proliferation and metastasis | |||
Cell apoptosis | ||||
Cell autophagy | ||||
In-vitro Model | Schwann cells (A type of glial cell that surrounds neurons) | |||
Lung cancer [ICD-11: 2C25]
In total 3 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as ATG5, ATG7, LC3B, and SQSTM1. beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II). beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
Responsed Disease | Non-small-cell lung carcinoma [ICD-11: 2C25.Y] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Chloroquine | Approved | ||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Autophagic lysosome acidification | |||
In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
Experiment 2 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as ATG5, ATG7, LC3B, and SQSTM1. beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II). beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
Responsed Disease | Non-small-cell lung carcinoma [ICD-11: 2C25.Y] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Gefitinib | Approved | ||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Autophagic lysosome acidification | |||
In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
Experiment 3 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as ATG5, ATG7, LC3B, and SQSTM1. beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II). beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
Responsed Disease | Non-small-cell lung carcinoma [ICD-11: 2C25.Y] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Beta-Elemen | Phase 3 | ||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Autophagic lysosome acidification | |||
In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
Chloroquine
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [2] | |||
Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as ATG5, ATG7, LC3B, and SQSTM1. beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II). beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Autophagic lysosome acidification | |||
In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
Gefitinib
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [2] | |||
Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as ATG5, ATG7, LC3B, and SQSTM1. beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II). beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Autophagic lysosome acidification | |||
In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
Beta-Elemen
[Phase 3]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [2] | |||
Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as ATG5, ATG7, LC3B, and SQSTM1. beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II). beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Autophagic lysosome acidification | |||
In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
References